Regulation 17 Amendment of regulation 19 (exemptions from requirement for wholesale dealer's licence)I1
United Kingdom
Regulation 19 M1 is amended as follows.
For paragraph (1)(a) substitute—
“(a)the holder of—
(i)in the case of a product for sale or supply in Great Britain, a UKMA(GB), a UKMA(UK), a COR(GB), a COR(UK), a THR(GB) or a THR(UK) (an “authorisation”) which relates to the product, or
(ii)in the case of a product for sale or supply in Northern Ireland, a UKMA(NI), a UKMA(UK), a COR(NI), a COR(UK), a THR(NI), a THR(UK), an EU marketing authorisation or an Article 126a authorisation (an “authorisation”) which relates to the product,
including a holder of an authorisation who manufactured or assembled the product; or”.
In paragraph (1)(b), after “or assembled the product” insert “ in the United Kingdom ”.
At the end insert—
“(6)Regulation 18 does not apply to a person (“P”) who imports a medicinal product into Great Britain from an approved country for import for administration to P or to any other person who is a member of P’s household.”.
Annotations
Textual amendments
- F1
Reg. 17(2) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 11(a)
- F2
Reg. 17(4) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 11(b)
Marginal citations
- M1
Regulation 19 was amended by S.I. 2013/1855.
Commencement
- I1
Reg. 17 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1